Resultados y vida financieraSalud - Farma - Biotecnología
Inside Information / Other news releases
05/11/2026 07:00
AMFPublicación inmediata
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026. “As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic…
INNATE PHARMA REPORTS THIRD QUARTER 2026 BUSINESS AND
FINANCIAL UPDATE
- Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
- Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027
- AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027
- Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028
- Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET
Marseille, France, November 5, 2026, 7:00 AM CET
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026. “As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.” 1 Including short term investments (€20.6m) and non-current financial instruments (€6.0m). Webcast and conference call will be held today at 2:00pm CET (8:00am ET) Access to live webcast:
Click here
Participants may also join via telephone using the registration link below:
Click here
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com.
A replay of the webcast will be available on the Company website for 90 days following the event.
Pipeline highlights
IPH4502 (Nectin-4 exatecan ADC):
- IPH4502 is Innate Pharma’s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).